TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18180682

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3%
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5%
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% and Moxifloxacin 0.5%
Number of subjects: 110
Study: 16760927

Group type: EXPERIMENTAL
Intervention: Risperidone augmentation (0.25-2.0 mg/day)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo augmentation
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Risperidone augmentation (0.25-2.0 mg/day) in fully nonresponsive patients
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo augmentation in fully nonresponsive patients
Number of subjects: 489
Study: 12831271

Group type: EXPERIMENTAL
Intervention: Monitor-mounted copy strip
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Copy strips and labeled product sleeves on stock bottles
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 110
Study: 10657266

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 72
Study: 9663833

Group type: EXPERIMENTAL
Intervention: 4 mg ABT-229
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 16 mg ABT-229
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8093495

Group type: EXPERIMENTAL
Intervention: Full-strength milk feeding
Number of subjects: 159

Group type: COMPARATOR
Intervention: Diluted milk feeding
Number of subjects: 159
Study: 3527181

Group type: EXPERIMENTAL
Intervention: suprofen syrup 10 mg/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: metamizole drops 50%
Number of subjects: 60
Study: 30950919

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Traditional Lecture-Based Approach
Number of subjects: 338
Study: 30399477

Group type: EXPERIMENTAL
Intervention: Moderate volume aerobic exercise (MA)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High volume aerobic exercise (HA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Moderate volume resistance exercise (MR)
Number of subjects: 5
Study: 8023772

Group type: EXPERIMENTAL
Intervention: < 60% diameter stenosis in the infarct-related artery
Number of subjects: 1752

Group type: COMPARATOR
Intervention: > or = 60% diameter stenosis with TIMI grade 2 or 3 flow
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Total occlusion (TIMI grade 0 or 1 flow)
Number of subjects: 1752
Study: 24887796

Group type: EXPERIMENTAL
Intervention: Surgical intervention (resection with or without plate fixation)
Number of subjects: 24
Study: 21490622

Group type: EXPERIMENTAL
Intervention: Successful anti-hypertensive treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normotensive individuals (control group)
Number of subjects: 41
Study: 20954414

Group type: EXPERIMENTAL
Intervention: Low level laser therapy and kinesy-therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Interferential current and kinesy-therapy
Number of subjects: 45
Study: 18296423

Group type: EXPERIMENTAL
Intervention: Ixabepilone 6 mg/m(2)/day x 5 days every 21 days (arm A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ixabepilone 20 mg/m(2) on days 1, 8, and 15 of a 28-day cycle (arm B)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Arm A (taxane-naive and taxane-exposed)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Arm B (taxane-naive and taxane-exposed)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Weekly ixabepilone 20 mg/m(2)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Common grades 3 and 4 toxic effects
Number of subjects: 85
Study: 16393729

Group type: EXPERIMENTAL
Intervention: Adenosine challenge
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (saline challenge)
Number of subjects: 42
Study: 14765564

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment system
Number of subjects: 413
Study: 10665721

Group type: EXPERIMENTAL
Intervention: SHP (Scientific Hip Prosthesis)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lubinus SP2 prosthesis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8886909

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (2000 mg 2‐3 hours before cisplatin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cisplatin (first course without methylprednisolone)
Number of subjects: 14
Study: 1303780

Group type: EXPERIMENTAL
Intervention: cyclosporin A, daily dose of 100 mg for 2 years
Number of subjects: 30

Group type: COMPARATOR
Intervention: not given cyclosporin
Number of subjects: 30
Study: 3000139

Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analogue (Org 2766)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 30952941

Group type: EXPERIMENTAL
Intervention: ranolazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 20
Study: 30170580

Group type: EXPERIMENTAL
Intervention: Capsular repair
Number of subjects: 259

Group type: COMPARATOR
Intervention: Capsular resection
Number of subjects: 259
Study: 26817624

Group type: EXPERIMENTAL
Intervention: IV iron
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study: 24694205

Group type: EXPERIMENTAL
Intervention: Low vitamin B12 group (B12 < 221 pmol/l)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal vitamin B12 group
Number of subjects: 53
Study: 22566538

Group type: EXPERIMENTAL
Intervention: Iron plus folic acid (12.5 mg of iron and 50 μg of folic acid)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Zinc (10 mg)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Iron plus folic acid and zinc
Number of subjects: 734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study: 20479662

Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sevoflurane/fentanyl anesthesia
Number of subjects: 96
Study: 18565127

Group type: EXPERIMENTAL
Intervention: Metformin 1500 or 2550 mg/day for 8 months
Number of subjects: 82
Study: 16004610

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: LPS stimulation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy non-smokers
Number of subjects: 41
Study: 12088463

Group type: EXPERIMENTAL
Intervention: Passive range of motion (PROM) exercises during phase A for group 1 (3 participants)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Passive range of motion (PROM) exercises during phase B for group 2 (3 participants)
Number of subjects: 6
Study: 10609921

Group type: EXPERIMENTAL
Intervention: DCLHb as an adjunct to standard therapy
Number of subjects: 112
Study: 7572107

Group type: EXPERIMENTAL
Intervention: Early menarche
Number of subjects: 3743

Group type: EXPERIMENTAL
Intervention: Late menarche
Number of subjects: 3743

Group type: EXPERIMENTAL
Intervention: Menarcheal age
Number of subjects: 3743
Study: 1657502

Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation at 50 litres/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation at 100 litres/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Citric acid inhalation at 50 litres/min
Number of subjects: 12
Study: 6355047

Group type: EXPERIMENTAL
Intervention: Acyclovir low dose (5 mg/kg every 8 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acyclovir high dose (500 mg/m2 every 8 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31665746

Group type: EXPERIMENTAL
Intervention: Micronutrient treatment (up to 12 capsules/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 29793736

Group type: EXPERIMENTAL
Intervention: High dependence smokers (TTFC ≤ 5 min after waking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dependence smokers (TTFC > 60 min after waking)
Number of subjects: 0
Study: 27582622

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) of active MTrPs in the trapezius muscle plus passive stretch
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CG) - passive stretch of the trapezius muscle only
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 44
Study: 24768410

Group type: EXPERIMENTAL
Intervention: CBT+CM
Number of subjects: 92
Study: 22583708

Group type: EXPERIMENTAL
Intervention: Family psychoeducation (four 2-hour multiple-family sessions)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 57
Study: 20176350

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 395

Group type: COMPARATOR
Intervention: White light (WL)
Number of subjects: 395
Study: 18023788

Group type: EXPERIMENTAL
Intervention: HIV testing (no specific intervention)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Baseline characteristics of adolescents who received HIV testing
Number of subjects: 1222
Study: 16220331

Group type: EXPERIMENTAL
Intervention: Ketamine (60-min infusion)
Number of subjects: 13
Study: 12103471

Group type: EXPERIMENTAL
Intervention: Dawn simulation (250 lux)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dim placebo signal (0.2‐2 lux)
Number of subjects: 50
Study: 10450009

Group type: EXPERIMENTAL
Intervention: Ureteral catheterization with patient mobilization (standing upright and walking 5 meters)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ureteral catheterization with patient mobilization (supine after walking 5 meters)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ureteral catheterization (all phases of maneuvers)
Number of subjects: 26
Study: 8528821

Group type: EXPERIMENTAL
Intervention: Outpatient, once a week group treatment for sexually abused girls
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 30
Study: 2222351

Group type: EXPERIMENTAL
Intervention: Nasal histamine (maximum nasal dose of 250 micrograms)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 22
Study: 7010527

Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0
Study: 31910803

Group type: EXPERIMENTAL
Intervention: Home-based computerized executive function training programme (12 weeks, 5 days a week, 30 min a day training, total dose = 30 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (waitlist group)
Number of subjects: 60
Study: 31131928

Group type: EXPERIMENTAL
Intervention: Tamsulosin combined with dapoxetine
Number of subjects: 251

Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 251
Study: 26488362

Group type: EXPERIMENTAL
Intervention: PFNA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PFLCP
Number of subjects: 90

Group type: COMPARATOR
Intervention: DHS
Number of subjects: 90
Study: 25736623

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 270
Study: 23461009

Group type: EXPERIMENTAL
Intervention: Reamberin 1.5% infusion
Number of subjects: 136

Group type: COMPARATOR
Intervention: Official therapy
Number of subjects: 136
Study: 21204695

Group type: EXPERIMENTAL
Intervention: High-immediacy level exposure on the PHR Web site
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control for privacy self-efficacy beliefs
Number of subjects: 252
Study: 18703544

Group type: EXPERIMENTAL
Intervention: Heidelberg Parent-based Language Intervention (HPLI), 3-month duration
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waiting group (control), 12-month waiting period
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Heidelberg Parent-based Language Intervention (HPLI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 61
Study: 17219106

Group type: EXPERIMENTAL
Intervention: Full macular translocation (FMT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 50
Study: 15687942

Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid 1g/125 mg administered from ovum pick-up day for 6 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid
Number of subjects: 101
Study: 11570828

Group type: EXPERIMENTAL
Intervention: CDE reminder‐feedback plus educational outreach (Intervention Group)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Screening program (Control Group)
Number of subjects: 318
Study: 9450157

Group type: EXPERIMENTAL
Intervention: pivagabine (900 mg/d)
Number of subjects: 100
Study: 7949210

Group type: EXPERIMENTAL
Intervention: 250 mg 4-hydroxyandrostenedione i.m. fortnightly
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 500 mg 4-hydroxyandrostenedione i.m. fortnightly
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 33
Study: 3048754

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1 IV
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1 IV
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 35
Study: 29563043

Group type: EXPERIMENTAL
Intervention: Community gardening
Number of subjects: 312

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 312
Study: 28453754

Group type: EXPERIMENTAL
Intervention: Once-daily mesalazine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Twice-daily mesalazine
Number of subjects: 83
Study: 26218845

Group type: EXPERIMENTAL
Intervention: B-GOS (galacto-oligosaccharide mixture)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 40
Study: 23999693

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus docetaxel
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab plus docetaxel
Number of subjects: 37
Study: 21055721

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis diagnosed by Nugent score ≥ 7 or vaginal pH ≥ 5
Number of subjects: 786

Group type: COMPARATOR
Intervention: Control group (women not assigned to cerclage)
Number of subjects: 786
Study: 18817348

Group type: EXPERIMENTAL
Intervention: Combined therapy (oral hydrochloric acid sertraline, local inunction of traditional Chinese medicine, guidance in sexual psychology and knowledge)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (oral hydrochloric acid sertraline only)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 17952073

Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis (AS)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Autoimmune thyroid disease (AITD)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1000
Study: 14975776

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (n = 29)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-intensity aerobic exercise (n = 25)
Number of subjects: 54
Study: 11944739

Group type: EXPERIMENTAL
Intervention: Selegiline, 5 mg, twice a day for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9170771

Group type: EXPERIMENTAL
Intervention: Intensive case management intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 202
Study: 7964693

Group type: EXPERIMENTAL
Intervention: Idazoxan (IDA)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 3299442

Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Blood Pressure Monitoring (BPM)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (part of BT)
Number of subjects: 158
Study: 29925383

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 0
Study: 27005294

Group type: EXPERIMENTAL
Intervention: Etomidate plus propofol
Number of subjects: 400

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 400
Study: 24767476

Group type: EXPERIMENTAL
Intervention: Community health workers with a tailored behavioral communication strategy and smartphone technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community health workers with an additional tailored behavioral communication strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (community health workers with the standard level of hypertension care training)
Number of subjects: 0
Study: 22077914

Group type: EXPERIMENTAL
Intervention: Low-pressure suction drainage of 50 mmHg
Number of subjects: 169

Group type: COMPARATOR
Intervention: High-pressure suction drainage of 700 mmHg
Number of subjects: 169
Study: 20973966

Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg/day for 25 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 18824949

Group type: EXPERIMENTAL
Intervention: 1 hour-educational session with a specially trained nurse
Number of subjects: 182

Group type: COMPARATOR
Intervention: Educational pamphlet
Number of subjects: 182
Study: 15619385

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 2082
Study: 12010234

Group type: EXPERIMENTAL
Intervention: Surgical treatment for penile fracture
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (200 men)
Number of subjects: 170
Study: 10660868

Group type: EXPERIMENTAL
Intervention: Ginseng (n = 7), receiving 350 mg of ginseng daily for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n = 8), receiving a placebo daily for 6 weeks
Number of subjects: 15
Study: 7848024

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: All losartan dosages
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily vs Losartan 100 mg once daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily vs Losartan 50 mg twice daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Addition of hydrochlorothiazide 12.5 mg/d
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Losartan (all dosages)
Number of subjects: 122
Study: 2332095

Group type: EXPERIMENTAL
Intervention: Pasta
Number of subjects: 14

Group type: COMPARATOR
Intervention: Couscous
Number of subjects: 14
Study: 367153

Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.5 microgram/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.0625, 0.125, 0.25, and 0.5 microgram/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-calcium meal (100 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-calcium meal (400 mg)
Number of subjects: 13
Study: 31795748

Group type: COMPARATOR
Intervention: Complex decongestive treatment (n=38)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Complex decongestive treatment + intermittent pneumatic compression (n=38)
Number of subjects: 76
Study: 31134436

Group type: EXPERIMENTAL
Intervention: 660‐nm diode laser; energy density = 1 J/cm2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 660‐nm diode laser; energy density = 3 J/cm2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 810‐nm diode laser; energy density = 1 J/cm2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 810‐nm diode laser; energy density = 3 J/cm2
Number of subjects: 40

Group type: COMPARATOR
Intervention: No laser treatment
Number of subjects: 40
Study: 28386033

Group type: EXPERIMENTAL
Intervention: Epidural romifidine (50μg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epidural detomidine (50μg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 18
Study: 25585599

Group type: EXPERIMENTAL
Intervention: Total n-3 PUFAs
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 556

Group type: COMPARATOR
Intervention: n-6 PUFAs
Number of subjects: 556
Study: 23370739

Group type: EXPERIMENTAL
Intervention: Pramipexole added to current medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching from ergot dopamine agonist to pramipexole
Number of subjects: 0
Study: 21081553

Group type: EXPERIMENTAL
Intervention: PTFE membrane
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Synthetic PEG
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of PTFE membrane and synthetic PEG
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 18
Study: 19958986

Group type: EXPERIMENTAL
Intervention: Vascugel
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 17719306

Group type: EXPERIMENTAL
Intervention: Water Exercise (WE)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Land Exercise (LE)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 15042481

Group type: EXPERIMENTAL
Intervention: Caroverine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine, Glutamate, Glutamic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11601957

Group type: EXPERIMENTAL
Intervention: Quality indicators for pneumonia management in vulnerable elders
Number of subjects: 0
Study: 9722252

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8974379

Group type: EXPERIMENTAL
Intervention: Acamprosate (calcium acetylhomotaurinate)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272